Activation of the transcription factor STAT3 is thought to potently promote oncogenesis in a variety of tissues, leading to intense efforts to develop STAT3 inhibitors for many tumors, including the highly malignant brain tumor glioblastoma. However, the function of STAT3 in glioblastoma pathogenesis has remained unknown. Here, we report that STAT3 plays a pro-oncogenic or tumor-suppressive role depending on the mutational profile of the tumor. Deficiency of the tumor suppressor PTEN triggers a cascade that inhibits STAT3 signaling in murine astrocytes and human glioblastoma tumors. Specifically, we forge a direct link between the PTEN-Akt-FOXO axis and the leukemia inhibitory factor receptor ␤ (LIFR␤)-STAT3 signaling pathway. Accordingly, PTEN knockdown induces efficient malignant transformation of astrocytes upon knockout of the STAT3 gene. Remarkably, in contrast to the tumor-suppressive function of STAT3 in the PTEN pathway, STAT3 forms a complex with the oncoprotein epidermal growth factor receptor type III variant (EGFRvIII) in the nucleus and thereby mediates EGFRvIII-induced glial transformation. These findings indicate that STAT3 plays opposing roles in glial transformation depending on the genetic background of the tumor, providing the rationale for tailored therapeutic intervention in glioblastoma.
Malignant gliomas of the brain, including the devastating tumor glioblastoma, represent a leading cause of cancer-related deaths in the young and middle-aged population (Jemal et al. 2003 ; Central Brain Tumor Registry of the United States 2002-2003 report, http://www.cbtrus. org). Few tumors carry worse prognosis than glioblastomas (Louis 2006; Furnari et al. 2007 ). The failed record of clinical trials in the treatment of these tumors may reflect the poorly understood biology of glioblastoma cells and their underlying signal transduction pathways (Stewart 2002; Konopka and Bonni 2003) . The majority of glioblastomas bear histologic features of cells along the astrocytic lineage ). These tumors are thus thought to arise from the transformation of astrocytes or their precursors, the neural stem cells (Holland 2001; Bachoo et al. 2002; Uhrbom et al. 2002; Bajenaru et al. 2003) . These observations raise the fundamental question of whether deregulation of signaling pathways that promote astrocyte differentiation during normal brain development might contribute to the pathogenesis of these devastating tumors. During brain development, neural stem cells differentiate into astrocytes (Ware et al. 1995; Bonni et al. 1997; Rajan and McKay 1998) . Activation of the cytokine receptor leukemia inhibitory factor receptor ␤ (LIFR␤) and downstream STAT3 signaling pathway stimulates the differentiation of neural stem cells into astrocytes (Ware et al. 1995; Bonni et al. 1997; Rajan and McKay 1998) . In addition to promoting astrocyte differentiation, recent studies suggest that STAT3 supports the renewal capacity of neural stem cells (Yoshimatsu et al. 2006) . The pleiotropic function of STAT3 in the development of cells along the glial lineage raises the interesting possibility that deregulation of STAT3 signaling might contribute to glial cell transformation.
What is the nature of STAT3 function in the pathogenesis of glioblastomas? STAT3 has been assigned a pro-oncogenic function in several cell types outside the nervous system (Bromberg et al. 1999; Chan et al. 2004; Chiarle et al. 2005; Ling and Arlinghaus 2005; Schlessinger and Levy 2005) . STAT3 activation has been described in a subset of glioblastomas (Wang et al. 2004; Weissenberger et al. 2004) , and STAT3 has been reported to promote the survival of some glioblastoma cell lines in vitro (Rahaman et al. 2002; Konnikova et al. 2003 ). These observations have provided the impetus to generate STAT3 inhibitors for a whole host of tumors including glioblastomas (Turkson et al. 2001; Leong et al. 2003; Song et al. 2005 ). Yet, the functional significance of STAT3 in the pathogenesis of glial malignancy has remained unknown. In addition, how STAT3 function is modulated in the setting of distinct oncogenic lesions known to drive glial cell transformation has been unexplored.
Loss-of-function mutations in the phosphatase PTEN on chromosome 10 are among the most common genetic abnormalities in high-grade gliomas Steck et al. 1997) . PTEN harbors a lipid phosphatase activity that figures prominently in its function as a glioblastoma tumor suppressor (Furnari et al. 1997 (Furnari et al. , 1998 . The lipid phosphatase activity of PTEN dephosphorylates phosphatidylinositol 3,4,5 trisphosphate (PIP 3 ) to produce phosphatidylinositol 4,5 bisphosphate (PIP 2 ). PIP 3 is a second messenger produced by phosphoinositide 3-kinase (PI3K) and activates its downstream effectors including the protein kinase Akt, a potent inducer of cell proliferation and survival (Cantley 2002) . Mutations in PTEN have been linked to tumors outside the brain, including breast, prostate, ovarian, and head and neck tumors Steck et al. 1997) . Thus, PTEN acts as a general tumor suppressor.
In this study, we find an unexpected tumor-suppressive function of STAT3 that is intimately linked to PTEN function. PTEN loss and consequent Akt activation suppresses the LIFR␤-STAT3 signaling pathway in astrocytes. Gene knockout studies reveal that STAT3 plays a key role in the PTEN pathway to suppress malignant transformation of astrocytes. In human glioblastomas, PTEN deficiency tightly correlates with inactivation of STAT3 signaling.
Strikingly, in contrast to STAT3's tumor-suppressive function in the PTEN pathway, STAT3 associates with the oncoprotein epidermal growth factor receptor type III variant (EGFRvIII) in the nucleus and thereby induces glial transformation. These findings indicate that STAT3 plays distinct roles in cell transformation depending on the oncogenic environment. Our study may thus provide the foundation for tailored therapy of glioblastomas based on their genetic profile.
Results

PTEN loss suppresses the LIFR␤-STAT3 signaling pathway
To investigate the role of glial developmental signaling pathways in tumorigenesis, we first determined if PTEN loss impacts on the LIFR␤-STAT3 signaling pathway in glial cells. We measured the levels of LIFR␤ in astrocytes in which the PTEN gene was disrupted by Cre-mediated excision of PTEN alleles flanked by loxP (floxed) sites. As predicted, little or no PTEN protein was detected in the Pten −/− astrocytes, and this was associated with enhanced phosphorylation of the serine/threonine kinase Akt on Ser 473, which reflects Akt activation (Fig. 1A,B (Fig. 1A,B) . These findings suggest that PTEN loss inhibits LIFR␤ expression in astrocytes.
We next characterized the mechanism by which PTEN loss suppresses LIFR␤ expression in astrocytes. PTEN catalyzes the dephosphorylation of the lipid messenger PIP 3 , which is generated by PI3K (Myers et al. 1997; Maehama and Dixon 1998) . Incubation of Pten −/− astrocytes with the PI3K inhibitor LY294002 restored LIFR␤ expression in these cells, suggesting that PTEN loss suppresses LIFR␤ expression via an increase in the levels of PIP 3 (Fig. 1C) . In addition, expression of a constitutively active Akt, a critical effector of PIP 3 (Cantley 2002) , in Pten loxP/loxP cells suppressed LIFR␤ expression (Fig. 1C) . Together, these results suggest that activated Akt inhibits LIFR␤ protein expression in PTEN-deficient astrocytes.
Consistent with the idea that PTEN loss triggers the inhibition of LIFR␤ gene expression, the levels of LIFR␤ mRNA measured by RT-PCR were significantly reduced in Pten −/− astrocytes (Supplemental Fig. S1 ). A major substrate of Akt is the transcription factor FOXO3, whose phosphorylation inhibits FOXO-dependent transcription (Burgering and Kops 2002; Van Der Heide et al. 2004) . Therefore, we asked whether the LIFR␤ gene might represent a direct target of FOXO3 in astrocytes and thus provide the basis for PTEN loss/activated Aktdirected suppression of LIFR␤ expression. We confirmed that endogenous FOXO3 was excluded from the nucleus and FOXO-dependent transcription was inhibited in astrocytes upon knockout of PTEN (Fig. 1D,E) .
By sequence analysis, we found a conserved FOXO-binding site within the promoters of the human, mouse, and dog LIFR␤ gene (data not shown). By chromatin immunoprecipitation (ChIP) analyses, endogenous FOXO3 occupied the endogenous LIFR␤ promoter in Pten loxP/loxP astrocytes (Fig. 1F ). However, little or no FOXO3 was found at the LIFR␤ promoter in Pten −/− astrocytes, suggesting that FOXO3 occupancy at the LIFR␤ gene correlates tightly with PTEN status and LIFR␤ expression in astrocytes (Fig. 1F) .
To determine the role of endogenous FOXO3 in the regulation of LIFR␤ expression in astrocytes, we used a lentiviral DNA template-based method of RNAi to knock down FOXO3 in these cells. We found that FOXO3 knockdown in PTEN-expressing (Pten loxP/loxP ) astrocytes suppressed LIFR␤ expression, mimicking the effect of PTEN knockout (Fig. 1G) . Taken together, our findings suggest that LIFR␤ is a direct target of FOXO3 in astrocytes and supports the conclusion that PTEN loss and consequent Akt activation inhibit FOXO3-dependent LIFR␤ gene expression in astrocytes (see model in Fig. 7A, below) .
To determine the consequences of the suppression of LIFR␤ expression in astrocytes, we measured the level of STAT3 that is phosphorylated at the key regulatory site Fig. S2 ). Taken together, these results suggest that PTEN loss suppresses the STAT3 signaling pathway in astrocytes.
STAT3 suppresses PTEN loss-induced malignant cell transformation
Suppression of STAT3 activation in astrocytes by inactivation of the tumor suppressor PTEN was unanticipated in view of the pro-oncogenic function of STAT3 in nonbrain cell and tumor types (Bromberg et al. 1999; Chan et al. 2004; Chiarle et al. 2005; Ling and Arlinghaus 2005; Schlessinger and Levy 2005) . Moreover, STAT3 has been reported to promote the survival of some glioblastoma cells in vitro (Rahaman et al. 2002; Konnikova et al. 2003) , and STAT3 activation as reflected by Tyr705 phosphorylation has been described in human gliomas (Weissenberger et al. 2004) . At the same time, other studies have provided evidence of the absence of STAT3 activity in a large percentage of these tumors including glioblastomas (Schaefer et al. 2002; Wang et al. 2004) , raising questions as to the relevance of STAT3 in glial tumorigenesis.
We decided to take a genetic approach to directly determine the role of STAT3 in glial cell transformation by assessing the effect of disruption of the STAT3 gene in astrocytes. We prepared astrocytes from mice carrying a homozygous floxed STAT3 allele (Stat3 loxP/loxP ) (Raz et al. 1999) , and induced knockout of the STAT3 gene by expressing the DNA recombinase Cre. STAT3 loss led to an increase in the number of astrocytes in cell population growth assays ( Fig. 2A) . In these experiments, STAT3 loss had little or no effect on cell death in astrocytes (data not shown). These results suggest that STAT3 inactivation stimulates astrocyte proliferation. We also examined the effect of knockout of STAT3 on the invasive potential of astrocytes. In matrigel invasion assays, we found that STAT3 knockout (Stat3 −/− ) astrocytes had significantly higher potential to invade through matrigel (Fig. 2B) . Thus, in addition to inducing astrocyte proliferation, STAT3 loss also increases the invasive potential of astrocytes. Together, these results raised the possibility that STAT3 might suppress astrocyte transformation.
To determine STAT3 function in astrocyte transformation, we tested the ability of Stat3 loxP/loxP and Stat3 −/− astrocytes to form tumors upon subcutaneous injection in severe combined immunodeficient (SCID) mice. Injection of astrocytes bearing the floxed or recombined STAT3 allele failed to form tumors (data not shown), suggesting that loss of the STAT3 gene on its own is insufficient to transform astrocytes.
Since the inhibition of STAT3 signaling in astrocytes occurred upon loss of PTEN ( Fig. 1) , we reasoned that STAT3 inactivation might cooperate with other events downstream from PTEN loss to promote glial malignancy. We therefore tested the effect of knockout of STAT3 on the behavior of astrocytes in which expression of the Pten gene was partially reduced by RNAimediated knockdown (PTEN shRNA ) (Fig. 2C ). STAT3 knockout significantly increased the number of PTEN shRNA astrocytes in cell population growth assays in vitro (Fig. 2D ). In addition, STAT3 loss had little or no effect on cell death in PTEN shRNA astrocytes (data not shown). Together, these results suggest that STAT3 knockout stimulates the proliferation of PTEN knockdown astrocytes.
Upon (Fig. 3A,B) . Histologic evaluation of the tumors revealed characteristic features of neoplastic transformation including nuclear atypia, pleomorphism, and frequent mitotic activity (Fig.  3C ). Tumors also expressed nestin, a marker of gliomas ( Fig. 3D ; Uhrbom et al. 2002; Dai and Holland 2003 (Fig. 3D) . Collectively, these results show that loss of STAT3 promotes astrocyte proliferation and invasiveness, and strongly potentiates astrocyte tumorigenesis upon knockdown of PTEN. Therefore, our studies strongly support the conclusion that STAT3 suppresses the malignant transformation of astrocytes in the context of the PTEN pathway.
STAT3 forms a physical complex with EGFRvIII in the nucleus and mediates EGFRvIII-induced cell transformation
The identification of a PTEN-regulated STAT3 tumorsuppressive function in astrocytes appeared paradoxical in view of the reported oncogenic function of STAT3. These observations led us to ask if STAT3 acts as a tumor suppressor under all circumstances or whether STAT3 function in astrocytes is dictated by the genotype of these cells. Besides PTEN loss, amplifications or rearrangements in the gene encoding the receptor tyrosine kinase (RTK) EGFR are important in the pathogenesis of de novo glioblastomas (Libermann et al. 1985; Wong et al. 1987) . A common mutant isoform of EGFR in glioblastomas is the EGFRvIII that lacks exons 2-7 and behaves as a constitutively active form of EGFR (Sugawa et al. 1990; Wong et al. 1992; Moscatello et al. 1996) . Expression of EGFRvIII in glial cells drives their malignant transformation (Nishikawa et al. 1994; Holland et al. 1998; Bachoo et al. 2002) . We confirmed that expression of EGFRvIII robustly triggers the malignant transformation of astrocytes (Fig. 5A-D, below) .
To assess the role of STAT3 in EGFRvIII-induced malignant glial transformation, we characterized the effect of EGFRvIII expression on STAT3 signaling. Activation of RTKs is thought to recruit STAT3 to the RTK at the plasma membrane followed by induction of STAT3 phosphorylation at the key regulatory sites Tyr705 and Ser727 and consequent translocation of STAT3 to the nucleus (Zhong et al. 1994; Leaman et al. 1996; Vignais et al. 1996; Decker and Kovarik 2000) . We asked if the constitutively active EGFRvIII recruits STAT3 and regulates its phosphorylation at the two key regulatory sites. We found that EGFRvIII interacted efficiently with STAT3, including endogenous STAT3 in astrocytes (Fig.  4A) . However, expression of EGFRvIII surprisingly failed to induce the STAT3 Tyr705 and Ser727 phosphorylation in astrocytes (Fig. 4B) . Similarly, EGFRvIII expression in human glioblastoma cells has a modest effect on STAT3 Tyr705 phosphorylation (Huang et al. 2007 ). Although activated RTKs are generally thought to induce the PI3K-Akt pathway (Cantley 2002; Kapoor and O'Rourke 2003) , EGFRvIII expression also had little effect on Akt activation in astrocytes (Fig. 4B) . Consistent with these results, whereas PTEN deficiency significantly reduced the STAT3 Tyr705 phosphorylation, EGFRvIII failed to reduce the STAT3 Tyr705 phosphorylation in astrocytes (Fig. 4B) .
Since EGFRvIII associated efficiently with STAT3 but failed to significantly alter STAT3 phosphorylation at Tyr705 or Ser727, we further characterized the interac- Cold
with STAT3. Several activated RTKs may translocate to the nucleus, raising the possibility of a direct signaling mechanism from the cell surface to the nucleus (Wells and Marti 2002; Carpenter 2003) . Subcellular fractionation analyses revealed that EGFRvIII, like STAT3, was present in both the nuclear and cytoplasmic fractions (Fig. 4C,D) . In addition, EGFRvIII staining was present in the nucleus as well as the cytoplasm in astrocytes in confocal fluorescence microscopy experiments (Fig. 4D) . Strikingly, EGFRvIII formed a physical complex with STAT3 more efficiently in the nuclear than cytoplasmic fraction (Fig. 4C) . These results suggest that the constitutively active EGFRvIII localizes in the nucleus where it associates with STAT3. Corroborating our findings, activated wild-type EGFR has been reported to interact with STAT3 in the nucleus leading to direct transcriptional activation of the pro-oncogenic genes VEGF and iNOS in breast cancer cells (Lo et al. 2005 ).
Expression of EGFRvIII in astrocytes stimulated iNOS expression in a STAT3-dependent manner as monitored by RT-PCR assays (data not shown). Taken together, these observations support the conclusion that EGFRvIII associates with STAT3 in the nucleus and raised the possibility that STAT3 might directly couple EGFRvIII signals to oncogenic responses in glial cells.
To determine STAT3 function in EGFRvIII-induced malignant astrocyte transformation, we assessed the effect of STAT3 knockout on the behavior of astrocytes expressing EGFRvIII (Fig. 5A) . In cell population growth experiments, STAT3 knockout led to a significant reduction in the number of EGFRvIII-expressing astrocytes (Fig. 5B) . In these assays, STAT3 loss had little or no effect on cell death (data not shown). Together, these results suggest that STAT3 promotes cell proliferation of astrocytes upon EGFRvIII expression.
We next measured the ability of Stat3 loxP/loxP ;EGFRvIII ;PTEN shRNA tumors (64% vs. 25%, respectively; average of two tumors each). Bar, 100 µm. ;EGFRvIII astrocytes to undergo malignant transformation upon injection into SCID mice (Fig. 5C,D) . We found that Stat3 loxP/loxP ;EGFRvIII astrocytes formed large tumors with histological features typical of malignancy, including nuclear atypia and frequent mitotic figures (Fig. 5C,D) . Remarkably, STAT3 knockout blocked the ability of EGFRvIII-expressing astrocytes to undergo malignant transformation (Fig. 5C ). Thus, in contrast to STAT3-mediated suppression of transformation in PTEN knockdown astrocytes, STAT3 is essential for EGFRvIII-mediated astrocyte transformation. Collectively, our results indicate that STAT3 has opposing functions in cell transformation depending on the genetic environment. While STAT3 has an oncogenic function in the context of EGFRvIII expression, STAT3 behaves as a tumor suppressor specifically in the PTEN pathway.
Identification of the opposing functions of STAT3 in glial transformation in the distinct setting of PTEN deficiency or EGFRvIII expression raised the intriguing question of the behavior of STAT3 in cells subjected to and Pten −/− astrocytes, or stable MSCV-GFP and MSCV-GFP/EGFRvIII astrocytes with antibodies that recognize Tyr705-phosphorylated STAT3 (pYS3), Ser727-phosphorylated STAT3 (pSS3), total STAT3, PTEN, Ser473-phosphorylated Akt (pAkt), total Akt, and EGFR. Actin was used as loading control. EGFRvIII expression had little effect on STAT3 Tyr705 and Ser727 phosphorylation. (C) Lysates of 293T cells transfected with Flag-STAT3, EGFRvIII, or both were fractionated into cytoplasmic and nuclear fractions and then subjected to immunoprecipitation and immunoblotting analyses as in A. SnoN and 14-3-3 were used as nuclear or cytosolic markers, respectively. EGFRvIII interacted with STAT3 more efficiently in the nuclear than in the cytoplasmic fraction. (D) EGFRvIII is present in the nucleus of astrocytes. (Top panel) Lysates of EGFRvIII-expressing and control astrocytes were subjected to subcellular fractionation and immunoblotting with the EGFR antibody. Lamin A and ␣-tubulin were used as nuclear or cytosolic markers, respectively. (Bottom panel) Immortalized astrocytes transfected with a plasmid encoding an EGFRvIII-GFP fusion protein were fixed and imaged by confocal microscopy to detect GFP fluorescence. Hoechst was used to visualize nuclei. Arrowheads indicate the position of the nucleus.
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STAT3 signaling in human glioblastomas
The elucidation of opposing STAT3 functions in PTEN loss-and EGFRvIII-induced transformation in genetic studies in mouse astrocytes prompted us to consider the role of STAT3 in human glial tumors. We addressed this question by measuring the levels of PTEN, EGFRvIII, and STAT3 Tyr705 phosphorylation in a panel of human glioblastoma specimens (Fig. 6A) . We monitored STAT3 phosphorylation in the human glioblastoma specimens by immunoblotting using a well-established phosphoTyr705-STAT3 antibody (Bonni et al. 1997) . Since STAT3 was inhibited in Pten −/− mouse astrocytes due to down-regulation of LIFR␤, we also assessed the levels of LIFR␤ in the glioblastoma specimens (Fig. 6A) . The levels of phosphorylated STAT3, LIFR␤, PTEN, and EGFRvIII were measured as continuous variables and normalized to GAPDH.
We found that EGFRvIII expression and low PTEN levels stratified into distinct tumors (Fig. 6A) . Upon subjecting the immunoblotting data to regression analysis, a positive correlation was found between PTEN expression and EGFRvIII expression with a Spearman rank correlation coefficient of r s = 0.582 (P < 0.05) (Fig. 6B) . These results are corroborated by other studies demonstrating that PTEN loss and EGFRvIII mark distinct molecular subsets of human glioblastoma, with a small subset of tumors displaying both genetic alterations (Choe et al. 2003; Mellinghoff et al. 2005) . Immunohistochemical analysis of human glioblastoma specimens expressing high levels of EGFRvIII revealed EGFRvIII immunoreactivity predominantly in the cytoplasm in tumor cells. Remarkably, EGFRvIII staining was also found in the nucleus in some tumor cells (Supplemental Fig. S3 ). In coimmunoprecipitation studies, EGFRvIII and STAT3 interacted in the nuclear fraction of glioblastomas expressing high EGFRvIII levels (Supplemental Fig. S4 ). These results corroborate our findings in mouse astrocytes, and suggest that EGFRvIII and STAT3 may form a physical nuclear complex in human glioblastomas.
We also found that low levels of PTEN were associated with down-regulation of LIFR␤ and phosphorylated STAT3 in human glioblastomas (Fig. 6A) . Regression analysis revealed a strong positive correlation between PTEN expression and LIFR␤ expression with a Spearman rank correlation coefficient of r s = 0.735 (P < 0.005) (Fig.  6C) . Similarly, levels of PTEN and phosphorylated STAT3 correlated tightly with a Spearman rank correlation value of r s = 0.541 (P < 0.05) (Fig. 6C) . Consistent with the interpretation that STAT3 and LIFR␤ act in a common signaling pathway, the levels of LIFR␤ and phosphorylated STAT3 also correlated in a highly significant manner, displaying a Spearman rank correlation coefficient of r s = 0.874 (P < 0.0001) (Fig. 6C) . Collectively, these findings demonstrate that PTEN loss and EGFRvIII mark distinct subsets of glioblastoma, and PTEN loss, but not EGFRvIII, is associated with inhibition of the LIFR␤-STAT3 signaling pathway in human glioblastomas.
Discussion
We discovered an unexpected tumor-suppressive function for STAT3 that is regulated by the tumor suppressor Cold Spring Harbor Laboratory Press on September 29, 2017 -Published by genesdev.cshlp.org Downloaded from PTEN. The major findings in this study are as follows: (1) Knockout experiments in mouse astrocytes demonstrate that STAT3 inhibits astrocyte proliferation and invasiveness in vitro and suppresses the malignant transformation of PTEN knockdown astrocytes in vivo. (2) PTEN loss, acting via the Akt-FOXO signaling pathway, triggers the down-regulation of the cytokine receptor LIFR␤ in astrocytes and consequently inhibits the phosphorylation of STAT3 at the key regulatory site Tyr705. (3) In human glioblastoma specimens, PTEN loss correlates tightly with low levels of LIFR␤ expression and inactivation of STAT3. (4) In contrast to the tumor-suppressive function of STAT3 in the PTEN pathway, STAT3 forms a physical complex with the pro-oncogenic protein EGFRvIII in the nucleus and mediates EGFRvIII-induced astrocyte transformation. Collectively, these findings reveal that STAT3 harbors distinct pro-oncogenic and tumor-suppressive functions that are dictated by key genetic alterations associated with glioblastoma (Fig. 7) . These results provide the foundation for the development of selective treatments in glioblastoma that are based on specific tumor-associated signaling events.
The identification of a STAT3 tumor-suppressive function may have significant ramifications in the management of glioblastoma. The prevailing view is that STAT3 acts as a general positive regulator of cell transformation and oncogenesis in diverse tissues including the brain (Bromberg et al. 1999; Turkson and Jove 2000; Chan et al. 2004; Chiarle et al. 2005; Schlessinger and Levy 2005) . This has led to intense efforts to develop inhibitors of STAT3 using small molecule, peptide, and decoy oligonucleotide approaches with the hope of treating many tumor types including brain tumors (Turkson et al. 2001; Leong et al. 2003; Song et al. 2005) . Our finding that STAT3 may operate in either a tumor suppressor or tumor-promoting capacity suggests that careful consideration must be given to STAT3 function and the associated genetic profile in each tumor type in order to determine whether inhibition of STAT3 activity might be ultimately beneficial or potentially harmful as a treatment strategy.
Analysis of the regulatory mechanisms underlying the unexpected tumor suppressor function of STAT3 in glial cells illuminates how loss of the tumor suppressor PTEN promotes the pathogenesis of glial tumors. Identification of the cytokine receptor LIFR␤ as a direct target of the transcription factor FOXO3 establishes a mechanism by which the PTEN-Akt-FOXO cascade modulates the glial developmental LIFR␤-STAT3 signaling pathway. The intersection of these two signaling networks allows PTEN loss to down-regulate LIFR␤ expression and inhibit STAT3 activity, thereby relieving STAT3's suppression of glial cell proliferation, invasiveness, and transformation. The inhibition of STAT3 signaling may thus constitute a mechanism by which PTEN loss induces a dedifferentiation program in astrocytes leading to their malignant transformation. Akt inhibition of the DNA-binding activity of STAT3 may also occur in glioblastoma cell lines, although the underlying mechanism is unclear (Ghosh et al. 2005 ). An important question for future investigation is whether the PTEN-regulated STAT3 tumor suppressor pathway operates specifically in glial cells or whether STAT3 might also function in a tumor-suppressive capacity in other cell types in which PTEN is a critical tumor suppressor. Interestingly, the PI3K-Akt signaling pathway may also inhibit STAT3 in melanoma cells, although the functional significance of STAT3 inhibition in these cells remains to be investigated (Krasilnikov et al. 2003) .
In stark contrast to the tumor-suppressive role of STAT3 in the PTEN pathway, STAT3 forms a physical complex with the pro-oncogenic protein EGFRvIII in the nucleus and thus mediates the ability of EGFRvIII to induce glial cell transformation. In the absence of either PTEN loss or EGFRvIII overexpression, STAT3 suppresses astrocyte cell proliferation and invasiveness. This is consistent with the view that the predominant function of STAT3 in astrocytes is to prevent malignant transformation. Thus, nuclear EGFRvIII may trigger a switch in the function of STAT3 from tumor suppressing to tumor promoting. A prediction of this hypothesis is that STAT3 might exert a tumor-promoting function in glioblastomas that are both PTEN-deficient and express EGFRvIII. Consistent with this conclusion, we found that STAT3 is required for the malignant transformation of astrocytes that are both PTEN-deficient and express EGFRvIII. In future studies, it will be interesting to determine the extent of nuclear EGFRvIII function in other tumors. The presence of EGFRvIII in the nucleus has been described in breast and prostate cancer (Ge et al. 2002; Edwards et al. 2006) . A nuclear protein complex comprising of activated wild-type EGFR and STAT3 activates transcription of pro-oncogenic genes in breast cancer cells (Lo et al. 2005) . Since EGFRvIII and STAT3 are expressed in many tumors (Bowman et al. 2000; Bromberg 2001; Pedersen et al. 2001; Lorimer 2002; Mizoguchi et al. 2006 ), a complex of nuclear EGFRvIII and STAT3 may thus act widely to promote malignant cell transformation.
Beyond EGFRvIII, the nuclear localization of membrane-bound RTKs, such as FGFR (fibroblast growth factor receptor) and wild-type EGFR, has been reported in diverse cell types (Maher 1996; Lin et al. 2001; Offterdinger et al. 2002) . Although the mechanism of nuclear localization of RTKs is unknown, several hypotheses have been proposed (Wells and Marti 2002; Carpenter 2003) . RTKs might reach the endoplasmic reticulum via the endocytic pathway, then might be extracted into the cytoplasm by the ERAD (endoplasmic reticulum-associated degradation) system (Tsai et al. 2002) , and transferred into the nucleoplasm by the nuclear import machinery (Carpenter 2003) . Alternatively, binding of chaperone-like factors to the receptor might mask the hydrophobicity of the membrane-spanning domain, allowing it to become soluble in the cytoplasm and translocate into the nucleus (Wells and Marti 2002) . The requirement of importin-␤ for nuclear translocation of FGFR and HER2 (Reilly and Maher 2001; Giri et al. 2005) suggests that the nuclear import machinery might participate in nuclear targeting of RTKs. Once in the nucleus, RTKs might regulate transcription, phosphorylate nuclear proteins, alter chromatin conformation, and/or modulate mRNA processing (Wells and Marti 2002) .
The elucidation of STAT3 as a dual regulator of PTEN loss-and EGFRvIII-induced glial malignancy in this study may provide clues for the design of patient-tailored therapies aimed at treating patients with glioblastomas according to their underlying molecular pathogenesis. STAT3 inhibitors may be useful in the treatment of glioblastomas in which EGFRvIII is amplified, while STAT3 activators may have therapeutic value in PTEN-deficient brain tumors. 
Materials and methods
Cell culture
Plasmids
The pcDNA3/EGFRvIII and pEGFP-N1/EGFRvIII constructs were obtained by subcloning from the MSCV-IRES-GFP/ EGFRvIII plasmid (kind gift from Dr. Alonzo Ross, University of Massachusetts Medical School) into pcDNA3 and pEGFP-N1, respectively.
Virus production and infection
Recombinant retroviruses were made by transfecting 293T cells with pMD.MLV gag.pol, pHDM.G (VSVG pseudotype), and the transfer plasmid (e.g., MSCV-IRES-GFP). Cells were infected with equal amounts of retroviruses and selected with the appropriate resistance drug or FACS-sorted for GFP expression.
Cloning of recombinant lentiviruses coding for a shRNA directed against FOXO was carried out using a modified pLL3.7 vector that encodes resistance to puromycin (pLL3.7 Puro). The following complementary oligonucleotides were inserted into pLL3.7 Puro: FOXOi fw, 5Ј-TGCGTGCCCTACTTCAAGGA TTCAAGAGATCCTTGAAGTAGGGCACGCTTTTTGGA AAC-3Ј; FOXOi rev, 5Ј-TCGAGTTTCCAAAAAGCGTGCC CTACTTCAAGGATCTCTTGAATCCTTGAAGTAGGGC ACGCA-3Ј. Hairpin structures containing the stem sequences (underlined) and the loops (bold italics) are indicated. Lentiviruses were generated by cotransfecting pLL3.7 and packaging vectors (VSVG, RSV-REV, and pMDL g/p RRE) into 293T cells. Cells were infected with equal amounts of lentiviruses and selected with puromycin.
The PTEN-encoding adenovirus was a kind gift from Dr. Christopher D. Kontos (Duke University School of Medicine).
ChIP
ChIP analyses were done as described (Shi et al. 2003) . Following immunoprecipitation, a PCR reaction was used to amplify the LIFR␤ promoter with the following primers: first PCR reaction, mouse LIFR␤ fw, 5Ј-TGTGGGAAAGAATGGGGATA-3Ј; mouse LIFR␤ rev, 5Ј-AACCGCTGTCATTGCACTTT-3Ј; nested PCR reaction, mouse LIFR␤ nest fw, 5Ј-CCAGAAAC AGTCATGGACAGC-3Ј; mouse LIFR␤ nest rev, 5Ј-GCGGAG GAGGAAACTCGT-3Ј. The following primers designed to amplify the E-cadherin promoter were used as negative controls for the PCR reaction: mouse E-cad fw, 5Ј-ACCGTCGGAGAA ATAGCTCA-3Ј; mouse E-cad rev, 5Ј-AACTTCCTCCACCCC TGTCT-3Ј.
Matrigel invasion assays
Matrigel precoated invasion chambers (BD) with an 8-µm pore size membrane were utilized according to the manufacturer's
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Mouse injections
Cells (1 × 10 6 ) were resuspended in serum-free, antibiotic-free media and injected subcutaneously into 4-to 6-wk-old SCID mice. Approximately 8 wk (PTEN knockdown astrocytes) or 4 wk (EGFRvIII astrocytes) after injection, the mice were sacrificed and the tumors were removed, measured, and fixed for histologic analysis.
Human tumor tissue samples
Discarded excess human glioblastoma tissue from neurosurgical specimens was collected and used in accordance with local IRB policies. Flash-frozen tumor tissue was processed for Western blotting analysis.
Statistical analysis
Correlation analysis of immunoblotting of human glioblastoma specimens was done by the nonparametric Spearman rank correlation test using the StatView statistics package.
Immunohistochemistry
Staining was performed on 5-µm paraffin sections. Sections were deparaffinized through xylenes and graded ethanol, and then rehydrated in PBS. Antigen retrieval was performed by microwaving for 20 min in 1 mM EDTA/5 mM Tris buffer (pH 8.0). The antibodies used were rabbit polyclonal against Ki-67 (Vector Laboratories), mouse monoclonal anti-Nestin (BD Biosciences), and mouse monoclonal anti-EGFRvIII (Skybio). Detection was performed with the Envision+ system (Dako) per the manufacturer's protocol.
